As of November 7, 2026, Aldeyra Therapeutics, Inc. is a publicly traded company (Nasdaq: ALDX); its largest reported holder is AQR, with 6.22% on Schedule 13G of August 12, 2026, then Barclays (5.48%) (Schedule 13G, August 12, 2026).
Is this your company?
About to sign with, pay or invest in Aldeyra Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aldeyra Therapeutics, Inc. a real, registered company?
- Aldeyra Therapeutics, Inc. files with the SEC under CIK 1341235 (its SEC filings).
- Its shares are listed under the ticker ALDX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Concord, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ALDEYRA THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Martin J. Joyce, Director (Form 8-K filed 2026-04-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Barclays (filed 2026-11-06).
Who are Aldeyra Therapeutics, Inc.'s owners and officers?
Aldeyra Therapeutics, Inc.: incorporated in Delaware; business address in Concord, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-06 | Barclays PLC | 5.48% |
| Schedule 13G, 2026-08-12 | Aqr Capital Management, LLC | 6.22% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 1.7% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 0% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Perceptive Advisors LLC | 7% |
| Schedule 13G/A, 2025-11-14 | Perceptive Advisors LLC | 8.7% |
| Schedule 13G/A, 2025-08-14 | Perceptive Advisors LLC | 6.8% |
Questions about who owns Aldeyra Therapeutics, Inc.
Who owns Aldeyra Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Aldeyra Therapeutics, Inc.: Aqr Capital Management, LLC (6.22%, Schedule 13G, filed 2026-08-12) and Barclays PLC (5.48%, Schedule 13G, filed 2026-11-06).
Who are the largest shareholders of Aldeyra Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aldeyra Therapeutics, Inc. on this page are Aqr Capital Management, LLC (6.22%) and Barclays PLC (5.48%).
When did Aqr Capital Management, LLC buy into Aldeyra Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Aqr Capital Management, LLC on this page is the Schedule 13G, filed 2026-08-12, reporting 6.22%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aldeyra Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aldeyra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aldeyra Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-20 | Martin J. Joyce | Director | departed |
Which insiders own Aldeyra Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Perceptive Life Sciences Master Fund Ltd., a 10% owner: 5,875,851 shares (9.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-07).
- , a 10% owner: 5,875,851 shares (9.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-07).
- Perceptive Advisors, a 10% owner: 5,875,851 shares (9.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-07).
- , the chief executive and president: 1,721,298 shares (2.9% of shares outstanding) (Form 4, 2026-06-05).
- , the chief development officer: 221,799 shares (0.37% of shares outstanding) (Form 4, 2025-08-13).
Shares outstanding: 60,356,541 as of 2026-11-03, from the company's latest SEC cover page.
How much has Aldeyra Therapeutics, Inc. raised?
No fundraising or offering filing from Aldeyra Therapeutics, Inc. is on file with us.
Keep reading
More on Aldeyra Therapeutics, Inc. and the records around it.
Aldeyra Therapeutics, Inc. elsewhere on the record
- Leadership changes Jun 2026
Companies that share a holder
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aldeyra-therapeutics